TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32683067

Group type: EXPERIMENTAL
Intervention: MUS placed for documented SUI
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Prophylactic MUS
Number of subjects: 134

Group type: COMPARATOR
Intervention: No MUS placed
Number of subjects: 134
Study: 35612382

Group type: COMPARATOR
Intervention: EVO (electrically evoked quadriceps contractions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: VOL (voluntary quadriceps contractions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: CON (no preexisting quadriceps fatigue)
Number of subjects: 10
Study: 32498113

Group type: EXPERIMENTAL
Intervention: Test formulation empagliflozin tablet under fasting condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reference formulation Jardiance under fasting condition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Test formulation empagliflozin tablet under fed condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Reference formulation Jardiance under fed condition
Number of subjects: 60
Study: 35131834

Group type: EXPERIMENTAL
Intervention: Imagined gait training with music, metronome, and verbal cueing
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Imagined gait training combined with actual gait training
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Actual gait training
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (15 matched healthy controls)
Number of subjects: 132
Study: 34363293

Group type: EXPERIMENTAL
Intervention: Intrapartum oxytocin administration
Number of subjects: 5484

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5484

Group type: EXPERIMENTAL
Intervention: Resuscitation of infants whose mothers received intrapartum oxytocin
Number of subjects: 5484

Group type: COMPARATOR
Intervention: Resuscitation of infants whose mothers did not receive intrapartum oxytocin
Number of subjects: 5484
Study: 32328912

Group type: EXPERIMENTAL
Intervention: Disclosure intervention
Number of subjects: 346

Group type: COMPARATOR
Intervention: Attention control case management
Number of subjects: 346
Study: 35450735

Group type: EXPERIMENTAL
Intervention: LSVT LOUD
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: LSVT ARTIC
Number of subjects: 65

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 65
Study: 33834341

Group type: EXPERIMENTAL
Intervention: Bioactive sulfur coated urea with 130 kg N ha‐1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Bioactive sulfur coated urea with 94 kg N ha‐1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sulfur coated urea with 94 kg N ha‐1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Coated fertilizers (neem-coated, sulfur-coated, bioactive sulfur-coated)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Coated fertilizers
Number of subjects: 3
Study: 36114623

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (40 ppm) during DL,NO manoeuvre
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo inhalations during DL,NO manoeuvre
Number of subjects: 9
Study: 33678639

Group type: EXPERIMENTAL
Intervention: Three high-tension line resection (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two high-tension line resection (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three high-tension line resection (Group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two high-tension line resection (Group D)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three high-tension line resection with anterior deviation (Group E)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Two high-tension line resection with anterior deviation (Group F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal endoscopy (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal endoscopy (Group B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhinomanometry (Group A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rhinomanometry (Group B)
Number of subjects: 0
Study: 33142544

Group type: EXPERIMENTAL
Intervention: Fermented liquor distiller's grains with solubles (FLDGS)
Number of subjects: 3300

Group type: COMPARATOR
Intervention: Unfermented liquor distiller's grains with solubles (ULDGS)
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Both ULDGS and FLDGS at various levels (4, 8, 12, 16, and 20%)
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: FLDGS
Number of subjects: 3300

Group type: EXPERIMENTAL
Intervention: Sources and levels of LDGS
Number of subjects: 3300
Study: 33559611

Group type: EXPERIMENTAL
Intervention: C‐phycocyanin (C‐PC) with small-molecule additives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C‐phycocyanin (C‐PC)
Number of subjects: 0
Study: 32145474

Group type: EXPERIMENTAL
Intervention: S-1 plus oxaliplatin (SOX) with pembrolizumab
Number of subjects: 54
Study: 36231728

Group type: EXPERIMENTAL
Intervention: Bright Light Therapy (BLT) for 30 min/day for 4 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo light
Number of subjects: 43
Study: 33691602

Group type: EXPERIMENTAL
Intervention: Online sexual intimacy enhancement training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Face-to-face sexual intimacy enhancement training
Number of subjects: 48
Study: 32639649

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Higher dose of Metformin
Number of subjects: 13
Study: 35845456

Group type: EXPERIMENTAL
Intervention: Cognitive Compensatory Training (CCT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Computerized Interactive Remediation of Cognition—Training for Schizophrenia (CIRCuiTs)
Number of subjects: 100

Group type: COMPARATOR
Intervention: CCT and CIRCuiTs (both groups)
Number of subjects: 100
Study: 32579298

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) of rosuvastatin/metformin sustained-release (10/1000 mg) in fasted and fed states
Number of subjects: 35

Group type: COMPARATOR
Intervention: Separate tablets of 10 mg rosuvastatin and 1000 mg metformin sustained release in the fed state
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Effect of food on pharmacokinetics
Number of subjects: 35
Study: 35767271

Group type: EXPERIMENTAL
Intervention: Prothrombin Complex Concentrate (PCC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Plasma
Number of subjects: 100
Study: 33971141

Group type: EXPERIMENTAL
Intervention: Apatinib 750 mg orally once daily
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 36076452

Group type: EXPERIMENTAL
Intervention: Oatmeal diet
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 62
Study: 33080623

Group type: EXPERIMENTAL
Intervention: Isatuximab monotherapy (20 mg/kg on days 1, 8, 15, and 22 of cycle 1 followed by 20 mg/kg on days 1 and 15 of subsequent cycles)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Isatuximab combined with dexamethasone (40 mg/d, 20 mg/d for patients aged ≥75 years, once weekly)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but inferred as patients not receiving dexamethasone)
Number of subjects: 164
Study: 36265267

Group type: EXPERIMENTAL
Intervention: Liberal O2 (SpO2 > 96%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conservative O2 (SpO2: 90–94%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conservative O2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Liberal O2
Number of subjects: 20
Study: 33883254

Group type: EXPERIMENTAL
Intervention: ADL-PF/ADL-PF
Number of subjects: 552

Group type: COMPARATOR
Intervention: ADL-EU/ADL-EU
Number of subjects: 552

Group type: COMPARATOR
Intervention: ADL-EU/ADL-PF
Number of subjects: 552
Study: 32078471

Group type: EXPERIMENTAL
Intervention: Whole body vibration exercise (WBVE) group (n = 17); 10 sessions (2 times/week), 18 min/session, frequency from 5 to 14 Hz, peak-to-peak displacement of 2.5, 5.0, and 7.5 mm
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (n = 16); same protocol as WBVE but with the vibrating platform turned off
Number of subjects: 33
Study: 36256584

Group type: EXPERIMENTAL
Intervention: Slow maxillary expansion (SME) activated once every other day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rapid maxillary expansion (RME) activated twice daily
Number of subjects: 30
Study: 33418095

Group type: EXPERIMENTAL
Intervention: Theta frequency bilateral STN stimulation (10 Hz)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gamma frequency bilateral STN stimulation (130–135 Hz)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Off stimulation
Number of subjects: 12
Study: 32683790

Group type: EXPERIMENTAL
Intervention: l-citrulline (3 g) daily for 2 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: microcrystalline cellulose (placebo) daily for 2 months
Number of subjects: 54
Study: 32779919

Group type: EXPERIMENTAL
Intervention: 10 mg prednisolone per day for 6 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34793405

Group type: EXPERIMENTAL
Intervention: Naltrexone (endogenous opioid antagonist)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 33808080

Group type: EXPERIMENTAL
Intervention: Collaborative deprescribing intervention by a pharmacist and a physician
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 72
Study: 32274521

Group type: EXPERIMENTAL
Intervention: Home-based stabilization exercises focusing on pelvic floor muscles (PFM) 3 days a week for 12 weeks, three sets a day; each set included three different types of exercise each week
Number of subjects: 80

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 80
Study: 35962772

Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Tacrolimus (TAC)
Number of subjects: 143
Study: 33967047

Group type: EXPERIMENTAL
Intervention: GRF6019
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GRF6019 and Placebo
Number of subjects: 26
Study: 32616263

Group type: EXPERIMENTAL
Intervention: 500 mg/kg VC
Number of subjects: 180

Group type: COMPARATOR
Intervention: 1,000 mg/kg VC
Number of subjects: 180

Group type: COMPARATOR
Intervention: SE challenge
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: VC supplementation
Number of subjects: 180
Study: 35218725

Group type: EXPERIMENTAL
Intervention: Standard of care plus individualized, point-of-purchase nutrition education
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Standard of care plus individualized, point-of-purchase nutrition education enhanced with online shopping technologies and training
Number of subjects: 267

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 267
Study: 33451596

Group type: EXPERIMENTAL
Intervention: 5% lidocaine patches
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo patches (hydrocolloid)
Number of subjects: 61
Study: 33518471

Group type: EXPERIMENTAL
Intervention: Topical xylometazoline (0.1%)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo (saline nasal spray, 0.74% w/v isotonic solution)
Number of subjects: 148
Study: 34644350

Group type: EXPERIMENTAL
Intervention: TEAM Wheels training program (peer-led teleconference training sessions and video-based training application)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (wait-list control)
Number of subjects: 0
Study: 35346603

Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 586

Group type: EXPERIMENTAL
Intervention: Bempedoic acid + ezetimibe fixed-dose combination
Number of subjects: 586

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 586
Study: 32043706

Group type: EXPERIMENTAL
Intervention: NaOCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EDTA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NaOCl/EDTA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 pH 12.6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ca(OH)2 pH 9.8
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formal-saline control-1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formal-saline control-2
Number of subjects: 0
Study: 36112645

Group type: EXPERIMENTAL
Intervention: US-detected group (n = 1,062)
Number of subjects: 1289

Group type: COMPARATOR
Intervention: US-missed group (n = 227)
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Blind spots (HCC ≥ 2 cm)
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: US-detected group (blind spot HCC)
Number of subjects: 1289

Group type: COMPARATOR
Intervention: Non-blind area HCC
Number of subjects: 1289
Study: 32379667

Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation (PMR) for 30 min per day for 5 consecutive days
Number of subjects: 51

Group type: COMPARATOR
Intervention: Routine care and treatment (Control)
Number of subjects: 51
Study: 34525122

Group type: EXPERIMENTAL
Intervention: Factor D (selenium/alpha‐tocopherol/beta‐carotene)
Number of subjects: 29553

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 29553
Study: 34880010

Group type: EXPERIMENTAL
Intervention: 200 mL convalescent plasma (CP) daily for up to 10 days (until virus negative in blood) plus standard care
Number of subjects: 900

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 900
Study: 32871264

Group type: EXPERIMENTAL
Intervention: Telehealth shoulder examination (STE)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard clinical examination (SCE)
Number of subjects: 62
Study: 35688014

Group type: EXPERIMENTAL
Intervention: Addiction risk information
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Addiction plus health risk information
Number of subjects: 1546

Group type: EXPERIMENTAL
Intervention: Addiction plus death risk information
Number of subjects: 1546

Group type: COMPARATOR
Intervention: No additional information (control)
Number of subjects: 1546
Study: 33573735

Group type: EXPERIMENTAL
Intervention: PFO closure using Amplatzer PFO Occluder
Number of subjects: 337

Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 337
Study: 32651582

Group type: EXPERIMENTAL
Intervention: Three referees
Number of subjects: 98

Group type: COMPARATOR
Intervention: One referee
Number of subjects: 98
Study: 35103547

Group type: EXPERIMENTAL
Intervention: Leukocyte-Rich Platelet-Rich Plasma (LR-PRP)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Leukocyte-Poor Platelet-Rich Plasma (LP-PRP)
Number of subjects: 192
Study: 33128303

Group type: COMPARATOR
Intervention: Aspartame (ASP) at a dose of 40 mg/kg/day
Number of subjects: 4

Group type: COMPARATOR
Intervention: Caffeine at a dose of 80 mg/kg/day
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Aspartame (ASP) and caffeine combined at previous doses
Number of subjects: 4
Study: 32486910

Group type: EXPERIMENTAL
Intervention: Orofacial pleasantness quantitative sensory testing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Orofacial unpleasantness quantitative sensory testing
Number of subjects: 16
Study: 34896605

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Treadmill training (TT)
Number of subjects: 44
Study: 34563924

Group type: EXPERIMENTAL
Intervention: Favipiravir (FPV)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Supportive therapy only
Number of subjects: 780
Study: 34015659

Group type: EXPERIMENTAL
Intervention: Sodium selenate (12.5 μg Se kg−1 soil)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (absence of Se)
Number of subjects: 29
Study: 33118519

Group type: EXPERIMENTAL
Intervention: Medical ozone oil (1 mL, applied locally 3 times per day for 12 weeks)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Urea ointment (10% urea, 2 g, applied locally 3 times per day for 12 weeks)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Medical ozone oil
Number of subjects: 91

Group type: COMPARATOR
Intervention: Urea ointment
Number of subjects: 91
Study: 34011342

Group type: EXPERIMENTAL
Intervention: Preoperative LMWH administration (4000 IU per day)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Postoperative LMWH administration (4000 IU per day)
Number of subjects: 246
Study: 32147037

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) plus exercise
Number of subjects: 40

Group type: COMPARATOR
Intervention: Combination of Ultrasound (US), Transcutaneous Nerve Stimulation (TENS) and exercise
Number of subjects: 40
Study: 35801815

Group type: EXPERIMENTAL
Intervention: Dual-focus contact lenses with 2.1 mm inner zone diameter (S design)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dual-focus contact lenses with 4.0 mm inner zone diameter (M design)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both dual-focus contact lenses
Number of subjects: 28
Study: 33706570

Group type: EXPERIMENTAL
Intervention: Mindful walking practice (usual care plus mindful walking)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Mindful walking practice
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 78
Study: 32429848

Group type: EXPERIMENTAL
Intervention: Mail-based recruitment strategy
Number of subjects: 13251

Group type: COMPARATOR
Intervention: Email-based recruitment strategy
Number of subjects: 13251
Study: 35175070

Group type: EXPERIMENTAL
Intervention: iSOMA intervention (8-week guided cognitive-behavioral internet intervention with psychologist support)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: iSOMA intervention
Number of subjects: 158

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 158
Study: 33947886

Group type: EXPERIMENTAL
Intervention: Random Forest (RF) classifier
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Feature-selected RF with serum potassium, plasma aldosterone, and serum sodium levels
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Feature-selected RF with an independent external PA cohort
Number of subjects: 229
Study: 33015809

Group type: EXPERIMENTAL
Intervention: Propofol administration (MED)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Model group (MOD)
Number of subjects: 3
Study: 33453066

Group type: EXPERIMENTAL
Intervention: TXA (inguinal region)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TXM (metacarpus)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: TXT (ventral tail base)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 6
Study: 33872284

Group type: EXPERIMENTAL
Intervention: Indocyanine green fluoroscopy
Number of subjects: 347

Group type: COMPARATOR
Intervention: Standard evaluation of tissue perfusion
Number of subjects: 347
Study: 36143973

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brachial Plexus Block (BPB)
Number of subjects: 0
Study: 33781915

Group type: EXPERIMENTAL
Intervention: Pabinafusp alfa at 1.0 mg/kg/week
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pabinafusp alfa at 2.0 mg/kg/week
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pabinafusp alfa at 4.0 mg/kg/week
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Pabinafusp alfa (all dosages)
Number of subjects: 3
Study: 35660738

Group type: EXPERIMENTAL
Intervention: Booster doses of CoronaVac
Number of subjects: 2
Study: 35606757

Group type: EXPERIMENTAL
Intervention: Online ESRD communication skills training (CST)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Regular in-service training (Control Group)
Number of subjects: 91
Study: 33085106

Group type: EXPERIMENTAL
Intervention: Cooled room
Number of subjects: 60

Group type: COMPARATOR
Intervention: Warmed room
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Identification with the suffering protagonist
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Para-social relationship with the protagonist
Number of subjects: 60
Study: 33343577

Group type: EXPERIMENTAL
Intervention: Quadrivalent inactivated influenza vaccines (QIVs)
Number of subjects: 16
Study: 35361657

Group type: EXPERIMENTAL
Intervention: Single pill containing quadruple combination of quarter doses of blood pressure medicines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard dose irbesartan
Number of subjects: 0
Study: 33124749

Group type: EXPERIMENTAL
Intervention: Caffeine intake of 180 mg shortly before surgery (intervention group)
Number of subjects: 2

Group type: COMPARATOR
Intervention: No caffeine (control group)
Number of subjects: 2
Study: 33296972

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) with low resistance (20% MIP for first 2 weeks, 30% MIP thereafter)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Respiratory exercise group (REG) with nasal breathing and maximum exhalation
Number of subjects: 67
Study: 36402670

Group type: EXPERIMENTAL
Intervention: Volanesorsen 300 mg weekly subcutaneous injection
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Volanesorsen
Number of subjects: 40
Study: 32525916

Group type: EXPERIMENTAL
Intervention: Hypertension prevalence
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Risk factors for hypertension
Number of subjects: 546
Study: 32149344

Group type: EXPERIMENTAL
Intervention: Smoking Abstinence
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Baseline MDE history
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Baseline depression severity
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Smoking status at FU
Number of subjects: 1000
Study: 33052103

Group type: EXPERIMENTAL
Intervention: Two‐compound gel once daily for 28 weeks
Number of subjects: 951

Group type: COMPARATOR
Intervention: Calcipotriol scalp solution twice daily for 28 weeks
Number of subjects: 951
Study: 616382680

Group type: EXPERIMENTAL
Intervention: Gepotidacin 750 mg intravenous every 12 hours (q12h)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg intravenous every 8 hours (q8h)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Gepotidacin 1,000 mg intravenous every 12 hours (q12h)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 122
Study: 36048411

Group type: EXPERIMENTAL
Intervention: Audio-visual storytelling
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Tell-show-do (TSD) technique
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45